US-based biotechnology company SalioGen Therapeutics announced on Monday that it has named Kalliopi 'Kali' Stasi, MD, PhD as its new chief medical officer.

In the new role, Dr Stasi will be responsible for bringing the firm's development candidate SGT-1001 into the clinic by mid-2025 as a one-time treatment for Stargardt disease, and continuing to develop the firm's Gene Coding technology for other inherited retinal diseases and cystic fibrosis.

Dr Stasi has worked as senior vice president of Clinical Development at Adverum Biotechnologies. She has served as senior vice president of Clinical Development at Tenpoint Therapeutic's cell therapy program for ophthalmic indications. She has also worked at Novartis Institutes for Biomedical Research as a translational medical director. She has worked for four years at the University of Pennsylvania as an assistant professor of Ophthalmology.

Jason Cole, SalioGen Therapeutics' CEO, said, 'Dr Stasi brings to SalioGen three decades of expertise in ophthalmology and a proven track record of advancing genetic medicines from early- and late-stage clinical development through commercialisation. Her clinical vision and leadership will enhance our ability to continue pushing the boundaries of genetic medicine for patients and families, and we're excited to welcome Dr Stasi to our team.'